pre-IPO PHARMA

COMPANY OVERVIEW

Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states.


LOCATION

  • Jupiter, FL, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders
  • Pain
  • Respiratory Disease

  • WEBSITE

    https://charlestonlabs.com/


    CAREER WEBSITE

    https://charlestonlabs.com/contact-us/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Apr 25, 2022

    Hyperalgesia Drugs in Development Report 2022: Featuring Caventure Drug Discovery, Charleston Laboratories, Exodos Life Sciences and Novartis


    Oct 17, 2017

    Charleston Laboratories, Inc. Resubmits NDA for CL-108


    Aug 31, 2017

    Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting


    Aug 31, 2017

    Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108


    Feb 15, 2017

    Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire


    For More Press Releases


    Google Analytics Alternative